|Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans.|
|Jump to Full Text|
|PMID: 23299892 Owner: NLM Status: MEDLINE|
|Candida albicans is the most common human fungal pathogen causing mucosal and systemic infections. However, human antifungal immunity remains poorly defined. Here by integrating transcriptional analysis and functional genomics, we identified Candida-specific host defence mechanisms in humans. Candida induced significant expression of genes from the type I interferon pathway in human peripheral blood mononuclear cells. This unexpectedly prominent role of type I interferon pathway in anti-Candida host defence was supported by additional evidence. Polymorphisms in type I interferon genes modulated Candida-induced cytokine production and were correlated with susceptibility to systemic candidiasis. In in vitro experiments, type I interferons skewed Candida-induced inflammation from a Th17 response towards a Th1 response. Patients with chronic mucocutaneous candidiasis displayed defective expression of genes in the type I interferon pathway. These findings indicate that the type I interferon pathway is a main signature of Candida-induced inflammation and has a crucial role in anti-Candida host defence in humans.|
|Sanne P Smeekens; Aylwin Ng; Vinod Kumar; Melissa D Johnson; Theo S Plantinga; Cleo van Diemen; Peer Arts; Eugène T P Verwiel; Mark S Gresnigt; Karin Fransen; Suzanne van Sommeren; Marije Oosting; Shih-Chin Cheng; Leo A B Joosten; Alexander Hoischen; Bart-Jan Kullberg; William K Scott; John R Perfect; Jos W M van der Meer; Cisca Wijmenga; Mihai G Netea; Ramnik J Xavier|
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't|
|Title: Nature communications Volume: 4 ISSN: 2041-1723 ISO Abbreviation: Nat Commun Publication Date: 2013|
|Created Date: 2013-01-09 Completed Date: 2013-06-20 Revised Date: 2014-03-19|
Medline Journal Info:
|Nlm Unique ID: 101528555 Medline TA: Nat Commun Country: England|
|Languages: eng Pagination: 1342 Citation Subset: IM|
|Data Bank Information|
Bank Name/Acc. No.:
|APA/MLA Format Download EndNote Download BibTex|
Candidemia / genetics, immunology, microbiology
Candidiasis, Chronic Mucocutaneous / genetics, immunology, microbiology
Gene Expression Regulation
Genetic Predisposition to Disease
Host-Pathogen Interactions / genetics*, immunology*
Interferon Type I / genetics*, immunology*
Mutation / genetics
Polymorphism, Single Nucleotide / genetics
STAT1 Transcription Factor / genetics
Signal Transduction / genetics*, immunology
Th1 Cells / immunology
Th17 Cells / immunology
|AI062773/AI/NIAID NIH HHS; DK043351/DK/NIDDK NIH HHS; DK83756/DK/NIDDK NIH HHS; P30 DK043351/DK/NIDDK NIH HHS; R01 AI062773/AI/NIAID NIH HHS; R01 DK060049/DK/NIDDK NIH HHS; R01 DK083756/DK/NIDDK NIH HHS|
|0/Interferon Type I; 0/STAT1 Transcription Factor|
Journal ID (nlm-journal-id): 101528555
Journal ID (pubmed-jr-id): 37539
Journal ID (nlm-ta): Nat Commun
Journal ID (iso-abbrev): Nat Commun
nihms-submitted publication date: Day: 6 Month: 3 Year: 2013
Print publication date: Year: 2013
pmc-release publication date: Day: 01 Month: 7 Year: 2013
Volume: 4First Page: 1342 Last Page: 1342
PubMed Id: 23299892
|Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans|
|Sanne P. Smeekens12*|
|Melissa D. Johnson67|
|Theo S. Plantinga12|
|Cleo van Diemen5|
|Eugéne T.P. Verwiel8|
|Mark S. Gresnigt12|
|Suzanne van Sommeren5|
|Leo A.B. Joosten12|
|William K. Scott9|
|John R. Perfect67|
|Jos W.M. van der Meer12|
|Mihai G. Netea12#|
|Ramnik J. Xavier34|
1Department of Medicine (463), Radboud University Nijmegen Medical Centre, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands
2Nijmegen Institute for Infection, Inflammation, and Immunity (N4i) (463), PO Box 9101, 6500 HB Nijmegen, The Netherlands
3The Broad Institute of Massachusetts Institute of Technology and Harvard University, 7 Cambridge Center, Cambridge MA 02142, USA
4Center for Computational and Integrative Biology and Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston MA 02114, USA
5Department of Genetics, University Medical Centre Groningen, P.O. Box 30001, 9700 RB Groningen, The Netherlands
6Duke University Medical Center, Duke Box 102359, Durham NC 27710 NC, USA
7Department of Clinical Research, Campbell University School of Pharmacy, PO Box 1090, Buies Creek NC 27506, USA
8Department of Human Genetics (855), Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
9Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, 1501 NW 10th Avenue Miami FL 33136, USA
|#Address for correspondence: Department of Medicine (463) Radboud University Nijmegen Medical Center Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands Tel: +31-24-3618819, Fax: +31-24-3541734 firstname.lastname@example.org
*These authors contributed equally to this work.
Candida albicans (C. albicans) is a commensal microorganism that inhabits human skin and mucosa. Candida can be isolated from up to 70% of the general population at any given moment, and it is believed that all individuals have been colonized with Candida at a some point1. Although it is a commensal organism, C. albicans can also cause mucosal and systemic infections, especially in immunocompromised hosts2. Despite the availability of novel classes of antifungal agents (e.g., azoles, echinocandins), mortality due to systemic candidiasis, the fourth most common form of sepsis3-5, reaches 37-44%3, 6, 7. In addition, vaginal and oral candidiasis can also occur in healthy or only mildly immunocompromised individuals8, with up to 5% of women in the general population suffering from recurrent vulvovaginal candidiasis9.
Despite the introduction of modern antifungal drugs and intensive care facilities, progress in improving the outcome of Candida infections in the last decade has been disappointing. Given this lack of progress, it is currently believed that only adjuvant immunotherapy will be able to further reduce the burden of morbidity and mortality caused by C. albicans infections10. Understanding the host defense pathways involved in candidiasis is therefore crucial for identifying novel targets for immunotherapy. To date, all investigations aimed at identifying antifungal host defense mechanisms in humans have relied on candidate-target approaches that are based on biologic plausibility of hypotheses extracted from in vitro or animal studies. While this approach has been fruitful in confirming important pathways of antifungal defense, it has lacked the power to provide a hierarchy of the importance of these pathways, and to identify potentially novel and unexpected host defense mechanisms against Candida.
In the present study, we have taken an alternative, unbiased approach to this biological problem. Using a combination of transcriptional analysis and systems biology, we have stimulated human primary cells with the fungus, identifying Candida-specific transcription profiles in human immune cells. While C. albicans induced the transcription of multiple inflammatory gene sets commonly stimulated by other inflammatory stimuli, it also specifically induced several additional gene sets, among which we identified an unexpectedly strong type I IFN signature profile. We confirmed the importance of the type I IFN pathway for anti-Candida host defense in humans through immunological and genetic studies in both healthy volunteers and in patients with systemic candidiasis or suffering from chronic mucocutaneous candidiasis (CMC).
We measured genome-wide transcriptional profiles in peripheral blood mononuclear cells (PBMCs) from healthy volunteers upon stimulation with C. albicans, as well as with inflammatory stimuli unrelated to fungal pathogens: Escherichia coli-derived lipopolysaccharide (LPS), Borrelia burgdorferi, Mycobacterium tuberculosis (MTB), and RPMI culture medium as a control. Measurements were performed at 4 and 24 hours. 693 transcripts that showed >2-fold higher expression compared to corresponding RPMI stimulation were selected (BH-adjusted P < 0.05). K-means analysis identified profile clusters that indicated shared and specific genes that were differentially expressed in response to each stimulus. We grouped shared genes into signatures representing common early response genes (clusters 1, 6, 14, 27), common late response genes (clusters 2, 3), and common inflammatory genes induced by all stimulations (clusters 9, 21, 25) (Fig. 1a and Supplementary Fig. S1-3).
More importantly, to identify a set of discriminatory features (from the 693 differentially expressed transcripts) that would be most informative of the state of Candida stimulation and could distinguish Candida stimulation from the other inflammatory stimuli, we utilized information gain (Kullback-Leibler divergence/relative entropy) feature selection, to reduce the dimensionality of the feature space11, 12. We performed 10-fold cross-validation which stratifies the data into 10 random partitions in which each (in turn) is held out for testing and the remainder for training a Bayesian classifier. Class prediction was evaluated by computing the area under the receiver-operating characteristic (ROC) curve (AUROC), which assesses true- and false-positive rates. A 101-transcript (95-gene) Candida-response signature (Fig. 1b and Supplementary Table S1) was defined using this supervised learning approach for class prediction, achieving an AUROC of 97.8%, which would indicate an excellent classifier performance with very high discriminative value. Principal component analysis (PCA) of the Candida-response signature further demonstrated good class separation on the basis of Candida status and stimulation duration (Fig. 1c). As a set, the 101 features collectively identify expression signatures that are informative of Candida stimulation across the 4-hour, 24-hour or both time-points that sufficiently distinguish Candida from the rest. Enrichment analysis for the 101-transcript Candida-response signature revealed a striking over-representation of the interferon (IFN) signaling pathway (p=3.8×10−35) (Fig. 1d and Supplementary Table S2). This set of genes was strongly induced at both 4 hours and 24 hours of Candida stimulation and establishes a definitive Candida-responsive signature distinct from that observed with LPS, MTB or Borrelia stimulation.
In order to assess whether the type I IFN genes specifically induced by C. albicans in human leukocytes are indeed involved in antifungal host defense, we investigated whether common polymorphisms in a subset of these genes influence susceptibility to systemic Candida infections. From a cohort of 217 Caucasian patients with candidemia, well described elsewhere10, 13, we had Immunochip genotyping data available and 11 genes of the 101-transcript (95-gene) dataset were covered by the Immunochip array (Supplementary Table S3). We tested these 11 genes for association by taking immunochip data on 12,228 non-candidemia Caucasian healthy volunteers as controls14. Analysis of the loci associated with these 11 genes revealed significant association of genetic variation with susceptibility to systemic candidiasis in four regions: CCL8 SNP 1kg_17_29697448 (p = 0.00069), STAT1 SNP rs16833172 (p = 0.0042), SP110 SNP rs3769845 (p = 0.012) and PSMB8 SNP rs3198005 (p = 0.01) (Fig. 2a-d) (Supplementary Fig. S1-3, clusters 10, 11, 20, 11 respectively) (Supplementary Table S3). After applying a stringent Bonferroni correction for multiple testing, the association between susceptibility to candidemia and STAT1 and CCL8 remained significant. This finding confirms that the C. albicans-specific genes we identified in our transcriptional arrays play an important role in host defense against systemic fungal infections. We also attempted to assess whether the polymorphisms in these genes also modified disease severity. However, only 51 patients fulfilled the criteria of severe candidiasis based on clinical scores and persistence of positive blood cultures, and this number was too low for allowing the identification of significant differences between genetic variation and disease severity (disseminated disease, persistent fungemia and mortality at 14 or 30 days) (data not shown).
In an additional approach to validate the role of the type I IFN pathway for host defense against Candida, we isolated PBMCs from an additional group of 74 healthy volunteers and stimulated the cells with the fungus. Genetic variation in 11 type I IFN pathway genes present on the Immunochip was correlated with C. albicans-induced release of TNF-α, IL-1β, IL-8, IL-6, IL-10, IFN-γ and IL-17. In contrast to other microbial stimuli such as LPS and MTB, C. albicans induced higher levels of TNF-α, IL-1β and IL-10 production, and lower levels of IL-8 and IL-6 in human PBMCs (Supplementary Fig. S4). The correlation of cytokine concentrations with genotypes at tag SNPs of Candida-induced IFN pathway genes revealed significant associations at IRF1 and STAT1 regions (Fig. 3a-d) in which IRF1 SNPs were associated with TNFα (p = 0.0028) and IL-10 levels (p = 0.0024), while STAT1 SNPs were associated with TNF-α (p = 0.001) and IL-6 levels (p = 0.0002). Consistent with the specificity of the type I IFN pathway for Candida stimulation, the association was significant with cytokine levels induced by Candida, but not by LPS or MTB stimulation (Supplementary Fig. S5).
To investigate the importance of type I IFN signaling in host defense against Candida, PBMCs from healthy individuals were stimulated with heat-killed C. albicans. In line with the transcriptional profile described above (Fig. 1), IFN-β could be detected in cell culture supernatants only after C. albicans stimulation. In contrast, neither live (Fig. 4a), nor heat-killed C. albicans induced any detectable IFN-α production
We next assessed the role of type I IFN pathways in the induction of cytokines by C. albicans. When PBMCs were stimulated with heat-killed C. albicans in the presence of an antibody against IFN-α/β/ω receptor 1 (IFNAR), IFNγ production was significantly lower compared to PBMCs stimulated in the presence of a control antibody. Blocking of IFNAR did not influence the production of the monocyte-derived cytokines IL-β or TNF-α (Fig. 4b). Conversely, adding IFN-α or IFN-β to Candida-stimulated cells increased IFN-γ production, while significantly decreasing IL-17 and IL-22 production (Fig. 4c). Together these data suggest that type I interferons (in the context of infection, most likely IFN-β) modulate the immune reaction induced by C. albicans, skewing host defense toward a Th1 response.
Patients with autosomal dominant CMC have increased susceptibility to mucosal fungal infections and often carry gain-of-function mutations in STAT115, 16, which lead to STAT1 hyperphosphorylation, that in turn likely makes STAT1 unavailable for forming heterodimers with other STAT molecules17. In co-cultures of DCs and T-cells from CMC patients, this led to defective Th1 and Th17 responses (Supplementary Fig. S6). In order to validate the role of Candida-specific genes in human antifungal mucosal defense, we assessed the expression of these genes in cells from CMC patients. PBMCs from healthy controls and CMC patients were stimulated with RPMI, E. coli-derived LPS, heat-killed C. albicans, or heat-killed MTB. The expression of type I IFN pathway genes (including IRF5, IRF7, ISG15, IFI44 and IFI44L) that are induced downstream of STAT1-STAT2 showed patterns of defective expression in CMC patients compared to healthy controls, supporting a role of the type I IFN pathway in this immunodeficiency (Fig. 5). The expression of IRF3, IRF9 and IFN-β, three genes in the type I IFN pathway upstream of STAT1-STAT2, was not decreased in cells from CMC patients. In fact, Candida induced IFN-β expression appeared to be higher in cells from CMC patients, possibly indicating a compensatory feedback mechanism.
In order to investigate the type I IFN pathway in CMC patients in a more systematic way, we also performed RNA sequencing analysis in PBMCs stimulated with C. albicans from both control volunteers and CMC patients. The differential expression of 91 genes in response to C. albicans stimulation was compared between CMC patients and healthy controls (10 genes from the 101-gene signature characteristic for Candida were not considered: 7 because another isoform was already used for FPKM calculations, and 3 hypothetical proteins without concordant refseq genes). In cells from healthy controls, two genes showed downregulation (LFNG, RGC32), while all other genes were upregulated upon stimulation (Supplementary Fig. S7), validating the previous findings based on expression array analysis. In order to observe differences between patients and controls, the standardized fold change was used to create the respective heatmap (Fig. 6). The patients show a much lower standardized fold change in genes downstream of STAT1, again supporting the role of type 1 IFN pathway in CMC. We found 27 genes, from the set of 91 genes, to be significantly differently regulated upon Candida stimulation in patients compared to controls based on an ANOVA analysis (p-value interaction group and treatment <0.05) (MX1, OAS3, IFIT2, RTP4, XAF1, OAS2, IFI44, IFIH1, IFIT3, ADAR, PRIC285, FAM46A, SAMD9L, EIF2AK2, PARP12, TRIM22, ZBP1, HERC6, RSAD2, IFNG, OAS1, STAT2, DHX58, IRF7, TNFSF10, ISG15, HERC5). To determine the role of these 27 genes we calculated Gene ontology (GO) enrichment scores using the Database for Annotation, Visualization and Integrated Discovery (DAVID). Enriched gene clusters were generated using Functional Annotation Clustering. Gene ontology terms associated with response to type I interferon and viral infections showed significant enrichment (p=1.09×10−14) (Supplementary Table S4).
The last decade has witnessed a significant increase in knowledge related to the mechanisms involved in antifungal host defense. However, most of this knowledge is based on in-vitro and animal studies; these studies led to hypotheses to be tested in human systems, leading to a somewhat biased view of human immunity against fungi. In the present study we have used a different approach based exclusively on complementary human studies: transcriptomics analysis in human primary cells, correlation of genetic variability and antifungal immunity in healthy volunteers (functional genomics), case-control association studies in patients with disseminated C. albicans infections, and assessment of antifungal immunity in CMC patients.
In our initial approach, we designed a hypotheses-generating set of experiments by assessing the transcriptional profile induced in circulating primary leukocytes by C. albicans. Human primary PBMCs were stimulated either with C. albicans or with other inflammatory stimuli. Pathway analysis of the genes induced by Candida indicated two broad categories: (i) a first set of genes that was strongly induced and shared by both C. albicans and other inflammatory stimuli (LPS, MTB, or B. burgdorferi), constituted expected pathways involved in inflammation and innate immunity, many of which have important roles in antifungal immunity18, and (ii) a feature set comprising an expression signature of 101 transcripts (95 genes) that distinguishes the Candida-specific response and is characterized by a strikingly strong and unanticipated type I IFN response.
Because the identification of the type I IFN pathway as the most prominent Candida-specific transcriptional signature was surprising, we initiated a series of studies to confirm this finding. Firstly, we assessed whether genetic polymorphisms in several of the genes identified in the Candida-specific dataset influenced susceptibility to systemic Candida infections. In a cohort of patients with candidemia that were genotyped using the Immunochip platform (Illumina14), on which 11 genes of the Candida-specific dataset were covered, we identified significant association of genetic variation with susceptibility to candidiasis in four of these genes: CCL8 locus, STAT1, SP110 locus, and PSMB8 locus. This finding confirms that genes from the 101 Candida-specific dataset influence susceptibility to systemic fungal infections.
Secondly, the role of the type I IFN pathway for the anti-Candida immune response was subsequently validated in a study in which PBMCs isolated from a group of healthy volunteers were stimulated with the fungus. Genetic variation in the 11 type I IFN pathway genes present on the Immunochip was correlated with C. albicans-induced cytokine production. The correlation of cytokine concentrations with genotypes at tag SNPs of Candida-induced IFN pathway genes revealed significant associations at IRF1 and STAT1 regions, both crucial components of type I IFN pathway. We cannot exclude however that the effect of these polymorphisms on TNFα production are exerted through type II interferons; IFNγ is stimulated by type I interferons19, and is known to induce TNF-α production20. These data support the hypothesis of the specificity of the type I IFN pathway for Candida stimulation, as this association was significant only for cytokine production induced by Candida, but not by other stimuli.
Thirdly, we performed classical immunological studies to assess the role of type I IFNs for Candida-induced immune responses, and we demonstrated that type I IFNs induced by Candida modulate Th1/Th17 cytokine profiles; IFNα and IFNβ increased IFNγ production, while decreasing IL-17 production. Moschen et al previously demonstrated that type I interferons decrease IL-17 production in vitro and in vivo.21 TNF-α production did not seem to be influenced by blocking the IFNAR, suggesting that genetic effects in STAT1 exert their effect on TNF-α production either through direct intracellular pathways, or indirectly through IFNγ. Interestingly C. albicans seems to induce only IFN-β, rather than IFN-α, consistent with earlier studies in mice22, 23.
Finally, using both qPCR and RNA sequencing analysis, we demonstrated that the expression of type I IFN pathway-induced genes was defective in CMC patients harboring a gain of function mutation in STAT115. These mutations lead to increased STAT1 phosphorylation and IFNγ signaling. Liu et al demonstrated increased STAT1 phosphorylation in response to IFNγ stimulation in U3C cells transfected with mutated STAT116. They hypothesize that IFN targeted genes can lead to decreased IL-17 production. However, freshly isolated PBMC from CMC patients do not produce any IFNγ in response to C. albicans stimulation15. Therefore, it is more likely that the inability of mutated STAT1 to form heterodimers with STAT3 and STAT4 causes defective Th1/Th17 responses17, which are likely to represent the main immunological defect in this disease. Additional defects in the expression of type I interferon-induced genes, as shown here, may also contribute to the increased susceptibility to mucosal fungal infections. Whether this is truly caused by a defect in STAT1-STAT2 heterodimerization remains to be demonstrated.
Taken together, these complementary studies represent a compelling body of evidence that the type I IFN pathway is an important component of the immune response during infections with C. albicans in humans. Moreover, the data presented here are supported by emerging information from murine studies. For example, Bourgeois et al. and Biondo et al. have reported that mouse conventional dendritic cells produce IFN-β upon stimulation with Candida spp. and have proposed a role for MyD88, TLR7 and TLR9 in this induction22, 23. On the other hand, these results are relatively surprising, as no earlier study has reported a role for type I IFNs in human antifungal host defense. In this respect, primary immunodeficiencies in type I IFN pathway are mainly associated with viral, rather than fungal, infections24. Therefore, our data suggest that type I IFN defects determine an increase susceptibility risk for fungal infections, as demonstrated here by the association with candidemia in risk groups, rather than an overt immunodeficiency associated with severe fungal infections.
The precise effect of type I IFNs for anti-Candida host defense is still being debated. One study in type I IFNAR knockout mice suggested a deleterious role for this pathway22, whereas another study reported that IFNAR−/− mice die from their inability to control fungal growth23. While type I IFNs play an important role in the immune response against viral infections25, they seem to be deleterious in bacterial infections26. In humans with Candida infections, the role of type 1 IFNs is not yet settled, although the defects seen in type I IFN gene expression in CMC patients, the susceptibility to candidemia by STAT1 polymorphisms, and the potentiation of Th1 responses by type I IFNs, all suggest a beneficial effect of the type I IFN pathway in human antifungal host defense.
Although viruses have long been known to induce type I IFN production, other microorganisms have been recently reported to induce this pathway. MTB stimulation induces the expression of IFNB and IFNA1 in human macrophages27 and in murine bone marrow-derived macrophages28; type I IFNs are required for caspase-1 activation during Francisella tularensis infection29; and Listeria monocytogenes induces the transcription of IFNB in macrophages30. However, the complete transcriptional profile of the type I IFN pathway performed here shows important differences from the type I IFN profile induced by MTB 31 and is significantly more pronounced for Candida than for MTB (Supplementary Fig. S4). Interestingly, the very strong induction of type I IFN pathway genes by Candida may explain the well-known, yet unexplained, beneficial effects of injecting Candida-derived extracts for the treatment of warts in patients32, 33.
In summary, this work presents complementary arguments from several studies to propose that the type I IFN pathway plays an important role in the immune responses to the fungal pathogen C. albicans in humans. The cross-validation between these approaches supports the value of this systems biology approach, combining transcriptomics with functional genomics and immunological data. Using this approach, we have confirmed the role of pathways known to be involved in antifungal host defense (e.g., common inflammatory pathways and the Th1/Th17 pathways) and we have identified a novel pathway (the type I IFN pathway). It is expected that this knowledge will have an important contribution in devising novel immunotherapeutic strategies for fungal infections, as well as influencing decision-making for vaccine design.
For assessing the transcriptome and the cytokine production capacity, blood was collected after written informed consent from healthy volunteers. Adult patients with candidemia were enrolled after informed consent (or waiver as approved by the Institutional Review Board) at the Duke University Hospital (DUMC, Durham, North Carolina, USA) and Radboud University Nijmegen Medical Centre (RUNMC, Nijmegen, The Netherlands). The study was approved by the Institutional Review Boards at each study center, and enrollment occurred between January 2003 and January 200934. The study was performed in accordance with the declaration of Helsinki. In addition, blood was collected from two patients with CMC (on two different occasions) and eight healthy controls in order to investigate the induction of IFN genes by Candida. After informed consent was given, blood was collected by venipuncture into 10 ml EDTA syringes (Monoject, s-Hertogenbosch, The Netherlands).
Separation and stimulation of peripheral blood mononuclear cells (PBMCs) was performed as described previously35. Briefly, the PBMC fraction was obtained by density centrifugation of diluted blood (1 part blood to 1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). PBMCs were washed twice in saline and suspended in culture medium. The cells were counted in a hemocytometer and their number was adjusted to 5·106/mL.
For the transcriptome analysis, cells were stimulated for 4 or 24 hours with RPMI, heat-killed Borrelia burgdorferi36, Candida albicans (UC 820)(1·106/mL)37, Mycobacterium tuberculosis (1 μg/mL) or E. coli-derived LPS (10 ηg/mL). In order to correlate cytokine production to SNPs in the type I IFN pathway, 5×105 PBMCs from healthy volunteers were stimulated with heat-killed C. albicans (1·106/mL) for 24 hours. In order to investigate the effect of type I IFNs on cytokine production, 5×105 PBMCs were stimulated with heat-killed C. albicans (1·106/mL) in the absence or presence of IFN-α2b (1·105 U/mL)(IntronA, SP Labo N.V., Heist-op-den-berg, Belgium), IFN-β (10 ng/mL), or anti-IFNAR (100 ηg/mL)(21385-1, PBL Inferon Source, Piscataway, USA). To assess the development of Th1 and Th17 cells, a total of 1×106 mononuclear cells was added to 96-wells flat-bottom plates (Greiner). Subsequently, the monocytes within the PBMC pool were differentiated towards dendritic cells (DCs) by addition of IL-4 (50 ng/ml, R&D Systems), GM-CSF (50 ng/ml, R&D Systems) and 10% human serum for seven days. After every second day, half of the medium was replaced by fresh DC differentiation medium. At day seven of the culture, cells were stimulated with 1×106Candida conidia for another six days.
Global gene expression was profiled using Illumina Human HT-12 Expression BeadChip according to manufacturer’s instructions. Image analysis, bead-level processing and quantile normalization of array data were performed using the Illumina LIMS platform, BeadStudio. A gene-wise linear model was fitted to the data and was performed in R programming language (http://www.r-project.org/), utilizing functions from Linear Models for Microarray Data38. For each probe, a moderated t-statistic (with standard errors moderated across genes) was computed using a Bayesian model. The associated p values were adjusted to control the false discovery rate in multiple testing, using the Benjamini and Hochberg’s (BH) method39. For each transcript, Signal-to-Noise ratios (SNR) were computed for each infection or stimuli group relative to the untreated (RPMI) control group. The expression SNR profiles of transcripts identified as differentially expressed (BH-adjusted p<0.05 and fold-change>2x) were clustered using the K-means algorithm40. We performed feature (attribute) selection41, 42 on differentially expressed transcripts using Information Gain (Kullback-Leibler divergence or relative entropy) to identify discriminatory features or transcripts that are most informative of the state of infection or stimulation. The accuracy of class prediction using a Java implementation of a naïve Bayes classifier42, 43 incorporating these features was evaluated using 10-fold cross-validation.
The concentration of IL-1β, IL-17, IL-22, TNF-α (R&D Systems, Abingdon, UK), IL-6, IL-8, IL-10, IFN-γ (Sanquin, Amsterdam, the Netherlands), and IFN-α, IFN-β (PBL Interferon Source, Piscataway, USA) was measured in cell culture supernatants using enzyme-linked immunosorbent assay (ELISA) according to the instructions of the manufacturer.
DNA was isolated using the Gentra Pure Gene Blood kit (Quiagen, Venlo, The Netherlands), according to the protocol of the manufacturer. Illumina Immunochip is a custom designed High-Density array to densely genotype 186 loci associated with 12 different autoimmune or inflammatory diseases reaching genome-wide association study significance threshold (P<5×10−8)14. The candidemia cohort and volunteers DNA samples were genotyped on this Immunochip Illumina platform. Only SNPs in 11 of the 101-gene dataset identified earlier were studied, as the other genes were not represented on the Immunochip. We selected tag-SNPs (Supplementary Table S3) at each region that are located within ± 250 kb of the locus by employing Haploview44 and we excluded SNPs with r2 ≥ 0.8 from association analysis.
Analyses were performed using PLINKv1.0745, 46. We performed Multidimensional scaling (MDS) analysis to reveal genetic background of cases and controls in Candidemia cohort (Supplementary Fig. S8). The association between tag-SNPs and Candidemia susceptibility was tested by logistic regression with the first four components from MDS analysis as covariates. The correlation between cytokine levels and genotypes was tested by Wilcoxon rank sum test using R. P-values less than 0.05 was considered significant.
Two million freshly isolated PBMCs were incubated with various stimuli as described above. After 24 hours of incubation at 37°C, total RNA was extracted in 800 μl of TRIzol reagent (Invitrogen, Breda, The Netherlands). Isolated RNA was reverse-transcribed into complementary DNA using oligo(dT) primers and MMLV reverse transcriptase. PCR was performed using a 7300 Real-Time PCR system (Applied Biosystems, Lennik, Belgium). Primer sequences for human IFN-β: sense: 5′- ATG-ACC-AAC-AAG-TGT-CTC-CTC-C-3′ and antisense: 5′- GGA-ATC-CAA-GCA-AGT-TGT-AGC-TC-3′; IRF9: sense 5′- GAT-ACA-GCT-AAG-ACC-ATG-TTC-CG-3′and antisense: 5′- TGA-TAC-ACC-TTG-TAG-GGC-TCA-3′; IRF7: sense: 5′- GCT-GGA-CGT-GAC-CAT-CAT-GTA-3′ and antisense: 5′- GGG-CCG-TAT-AGG-AAC-GTG-C-3′; ISG15: sense: 5′- CGC-AGA-TCA-CCC-AGA-AGA-TCG-3′ and antisense: 5′- TTC-GTC-GCA-TTT-GTC-CAC-CA-3′; IFI44: sense: 5′- ATG-GCA-GTG-ACA-ACT-CGT-TTG-3′ and antisense: 5′- GCA-GGA-TCT-TTC-GTG-CAA-CC-3′; IFI44L: sense: 5′- AGG-GAA-TCA-TTT-GGC-TCT-GTA-GA-′3 and antisense: 5′- AGC-CGT-CAG-GGA-TGT-ACT-ATA-AC-3′; IRF3: sense: 5′-AGA-GGC-TCG-TGA-TGG-TCA-AG-3′ and antisense: 5′-AGG-TCC-ACA-GTA-TTC-TCC-AGG-3′; IRF5: sense: 5′-GGG-CTT-CAA-TGG-GTC-AAC-G-3′ and antisense: 5′-GCC-TTC-GGT-GTA-TTT-CCC-TG-3′. B2M was used as a reference gene, for which the primers were: 5- ATG-AGT-ATG-CCT-GCC-GTG-TG-3 (forward) and 5- CCA-AAT-GCG-GCA-TCT-TCA-AAC-3 (reverse). PCR conditions were as follows: 2 minutes at 50°C and 10 minutes at 95°C, followed by 40 cycles of PCR reaction at 95°C for 15 seconds, and 60°C for 1 minute.
RNA sequencing experiments were performed on 4 hour unstimulated and C. albicans-stimulated PBMC from three healthy controls and two CMC patients. Total RNA was isolated as described above. The RNA integrity (RNA integrity score ≥ 7) was measured on the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, USA) using an Agilent RNA 6000 Pico Chip according to the manufacturer’s instructions. Enrichment of mRNA was done using the MicroPoly(A)Purist Kit (Ambion, Life Technologies, Foster City, USA) according to manufacturer’s instructions, starting with 5μg of total RNA and using two rounds of Oligo(dT) selection. Whole transcriptome library preparation was performed using the SOLiD Total RNA-Seq Kit (STaR Kit, Life Technologies) and the corresponding low input amount protocol (version July 2011, Life Technologies). In brief, 25ng high quality poly(A) RNA was fragmented by RNAse III digestion, cleaned up using the PureLink RNA Micro Kit (Invitrogen, Life Technologies) and checked for quantity and size-distribution on a Agilent 2100 Bioanalyzer. RNA adapters were hybridized and ligated to the fragmented RNA, followed by reverse transcription. After purification and size-selection of cDNA using Agencourt AMPure XP Reagent beads, the cDNA was amplified and used as input for the SOLiD system bead preparation using the SOLiD Easy bead system (E120 scale). Paired-end sequencing (50+25 bases) was performed on one flowcell of a 5500XL sequencer (Life Technologies) For each sample deep sequencing was performed resulting in a sequencing depth ranging from 75.6 million to 105.5 million paired-end reads. Paired-end colorspace reads were mapped against the human genome (hg19) using Tophat (version 1.4.1)47. To increase mapping performance a GTF-file containing the exon boundries of all known RefSeq genes (25,024 genes) was supplied to Tophat and the insert size was set to 110 bases. For all genes FPKM (Fragments per Kilobase per Million mapped reads) values were calculated using Cufflinks (version 2.0.0)48. Further statistical analyses was done using Partek® Genomic Suite software (version 6.6, build 6.12.0109, Partek Inc., St. Louis, USA). Fold changes and p-values were calculated for each gene by performing a multifactorial Analysis of Variance (ANOVA) on log2 (with an offset of 1.0) transformed FPKM expression values. Factors included in the ANOVA model were group (patient or control), treatment (stimulation status), individual (data from same individual), and the interaction between group and treatment. Fold changes for the heatmaps were calculated for each individual by dividing the FPKM expression values of the C. albicans stimulated sample by the unstimulated (RPMI) sample. Fold changes with values below 1 were replaced by the negative of the inverse. A gene list containing 101 differentially expressed transcripts known from the expression array was used to select genes for further downstream analysis. Of this list, 10 transcripts were not considered; 7 because another isoform was already used for FPKM calculations, and 3 hypothetical proteins without concordant refseq genes.
FN2The authors declare no conflicting financial interests.
FN3Transcriptomics data have been deposited in the Gene Expression Omnibus (GEO) database under accession code GSE42606.
FN4AUTHOR CONTRIBUTIONS L.A.B.J., W.K.S., J.R.P., J.W.M.M., C.W., M.G.N. and R.J.X. designed the research, S.P.S., A.N., V.K., M.D.J., T.S.P., P.A, E.T.V, A.H., C.D., A.G., M.S.G., K.F., S.S., M.O., S.C.C. performed the research and analyzed the data, S.P.S., A.N., V.K., C.W., M.G.N. and R.J.X. interpreted the data and wrote the paper.
RJX was supported by National Institutes of Health grants AI062773, DK043351 and DK83756 and the Helmsley Trust. MGN was supported by an ERC Consolidator grant (ERC-310372). The work in the group of CW is financially supported by the Coeliac Disease Consortium, an Innovative Cluster approved by the Netherlands Genomics Initiative and funded by the Dutch Government (BSIK03009), and by the Netherlands Organization for Scientific Research (NWO VICI grant 918.66.620). We would like to thank Fadi Towfic for helpful discussions, Mathieu Platteel, Astrid Maatman, Soesma Medema-Jankipersadsing, Rutger Modderman, Judith Land and Gosia Trynka for assisting in the stimulation experiments, RNA and DNA analysis, and microarray experiments (immunochip and gene expression). Furthermore, the authors thank Kornelia Neveling and Petra de Vries for technical assistance with the RNA sequencing experiments.
|1.||Mavor AL,Thewes S,Hube B. Systemic fungal infections caused by Candida species: epidemiology, infection process and virulence attributesCurrent drug targetsYear: 2005686387416375670|
|2.||Wingard JR,Merz WG,Saral R. Candida tropicalis: a major pathogen in immunocompromised patientsAnn. Intern. MedYear: 197991539543384857|
|3.||Wisplinghoff H,et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance studyClin Infect DisYear: 20043930931715306996|
|4.||Wisplinghoff H,et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilitiesThe Pediatric infectious disease journalYear: 20032268669112913767|
|5.||Wisplinghoff H,Seifert H,Wenzel RP,Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United StatesClin Infect DisYear: 2003361103111012715303|
|6.||Leroy O,et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006)Crit. Care MedYear: 2009371612161819325476|
|7.||Moran C,Grussemeyer CA,Spalding JR,Benjamin DK Jr.,Reed SD. Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infectionsAm. J. Infect. ControlYear: 201038788019836856|
|8.||Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidiasisAnn. N. Y. Acad. SciYear: 19885445475573063184|
|9.||Sobel JD. Vulvovaginal candidosisLancetYear: 20073691961197117560449|
|10.||Johnson MD,et al. Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort StudyClin Infect DisYear: 2011|
|11.||Li T,Zhang C,Ogihara M. A comparative study of feature selection and multiclass classification methods for tissue classification based on gene expressionBioinformaticsYear: 2004202429243715087314|
|12.||Dudoit S,F. J,Speed TP. Comparison of discrimination methods for the classification of tumors using gene expression dataJ. Am. Stat. AssocYear: 2002977787|
|13.||Plantinga TS,et al. Toll-like receptor 1 polymorphisms increase susceptibility to candidemiaThe Journal of infectious diseasesYear: 201220593494322301633|
|14.||Trynka G,et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac diseaseNature geneticsYear: 2011431193120122057235|
|15.||van de Veerdonk FL,et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasisThe New England journal of medicineYear: 2011365546121714643|
|16.||Liu L,et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasisThe Journal of experimental medicineYear: 20112081635164821727188|
|17.||Smeekens SP,et al. STAT1 Hyperphosphorylation and Defective IL12R/IL23R Signaling Underlie Defective Immunity in Autosomal Dominant Chronic Mucocutaneous CandidiasisPloS oneYear: 20116e2924822195034|
|18.||Netea MG,Brown GD,Kullberg BJ,Gow NA. An integrated model of the recognition of Candida albicans by the innate immune systemNat Rev MicrobiolYear: 20086677818079743|
|19.||Way SS,Havenar-Daughton C,Kolumam GA,Orgun NN,Murali-Krishna K. IL-12 and type-I IFN synergize for IFN-gamma production by CD4 T cells, whereas neither are required for IFN-gamma production by CD8 T cells after Listeria monocytogenes infectionJ ImmunolYear: 20071784498450517372008|
|20.||Vila-del Sol V,Punzon C,Fresno M. IFN-gamma-induced TNF-alpha expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophagesJ ImmunolYear: 20081814461447018802049|
|21.||Moschen AR,Geiger S,Krehan I,Kaser A,Tilg H. Interferon-alpha controls IL-17 expression in vitro and in vivoImmunobiologyYear: 200821377978718926293|
|22.||Bourgeois C,et al. Conventional dendritic cells mount a type I IFN response against Candida spp. requiring novel phagosomal TLR7-mediated IFN-beta signalingJ ImmunolYear: 20111863104311221282509|
|23.||Biondo C,et al. Recognition of yeast nucleic acids triggers a host-protective type I interferon responseEuropean journal of immunologyYear: 2011411969197921480215|
|24.||Sancho-Shimizu V,de Diego RP,Jouanguy E,Zhang SY,Casanova JL. Inborn errors of anti-viral interferon immunity in humansCurr Opin VirolYear: 2011148749622347990|
|25.||Lopez CB,Hermesh T. Systemic responses during local viral infections: type I IFNs sound the alarmCurrent opinion in immunologyYear: 20112349549921752617|
|26.||Decker T,Muller M,Stockinger S. The yin and yang of type I interferon activity in bacterial infectionNature reviewsYear: 20055675687|
|27.||Novikov A,et al. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1beta production in human macrophagesJ ImmunolYear: 20111872540254721784976|
|28.||Pandey AK,et al. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosisPLoS PathogYear: 20095e100050019578435|
|29.||Henry T,Brotcke A,Weiss DS,Thompson LJ,Monack DM. Type I interferon signaling is required for activation of the inflammasome during Francisella infectionThe Journal of experimental medicineYear: 200720498799417452523|
|30.||Stockinger S,et al. Production of type I IFN sensitizes macrophages to cell death induced by Listeria monocytogenesJ ImmunolYear: 20021696522652912444163|
|31.||Berry MP,et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosisNatureYear: 201046697397720725040|
|32.||Clemons RJ,Clemons-Miller A,Johnson SM,Williamson SK,Horn TD. Comparing therapy costs for physician treatment of wartsJ Drugs DermatolYear: 2003264965414711145|
|33.||Horn TD,Johnson SM,Helm RM,Roberson PK. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trialArch. DermatolYear: 200514158959415897380|
|34.||Rosentul DC,et al. Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemiaThe Journal of infectious diseasesYear: 20112041138114521881131|
|35.||Netea MG,et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptorsJ. Clin. InvestYear: 20061161642165016710478|
|36.||Oosting M,et al. TLR1/TLR2 Heterodimers Play an Important Role in the Recognition of Borrelia SpirochetesPloS oneYear: 20116e2599821998742|
|37.||Lehrer RI,Cline MJ. Interactions of Candida albicans with human leukocytes and serumJ. BacteriolYear: 19699899610044182532|
|38.||Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experimentsStat Appl Genet Mol BiolYear: 20043 Article3.|
|39.||Benjamini Y,Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testingJ R Stat SocYear: 199557289300|
|40.||Huang Z. Year: 1997SIGMOD Workshop on Research Issues on Data Mining and Knowledge DiscoveryTucsonAZ, USA|
|41.||Xing EP,Jordan MJ,Karp RM. Brodley CE,Danyluk APEighteenth International Conference on Machine LearningYear: 2001601608Morgan KaufmannWilliamstown, MA, USA|
|42.||Witten IH,Frank E,Hall MA. Data mining: practical machine learning tools and techniquesYear: 2011Morgan Kaufmann.Edn. 3rd Edition|
|43.||Langley P,Iba W,Thompson K. Swartout WRTenth National Conference on Artificial IntelligenceYear: 1992223228The MIT PressSan Jose, CA, USA|
|44.||Barrett JC,Fry B,Maller J,Daly MJ. Haploview: analysis and visualization of LD and haplotype mapsBioinformaticsYear: 20052126326515297300|
|45.||Purcell S. Edn. PLINK 1.07 http://pngu.mgh.harvard.edu/purcell/plink/.|
|46.||Purcell S,et al. PLINK: a tool set for whole-genome association and population-based linkage analysesAmerican journal of human geneticsYear: 20078155957517701901|
|47.||Trapnell C,Pachter L,Salzberg SL. TopHat: discovering splice junctions with RNA-SeqBioinformaticsYear: 2009251105111119289445|
|48.||Roberts A,Pimentel H,Trapnell C,Pachter L. Identification of novel transcripts in annotated genomes using RNA-SeqBioinformaticsYear: 2011272325232921697122|
Previous Document: Kinship reduces alloparental care in cooperative cichlids where helpers pay-to-stay.
Next Document: The bipolar assembly domain of the mitotic motor kinesin-5.